HFA Premium Access

Phase ii trial of pharmacogenetic guided beta-blocker therapy with bucindolol vs. metoprolol for the prevention of atrial fibrillation/flutter in heart failure: GENETIC-AF

Congress Session

About the speaker

Professor William Abraham

The Ohio State University, Columbus (United States of America)
39 presentations
1 follower

11 more presentations in this session

The HF-Wii study: Improving exercise capacity of patients with heart failure through exergaming: Secondary outcomes and per protocol analysis of an international multicenter RCT

Speaker: Professor T. Jaarsma (Linkoping, SE)


Discussion - HF-Wii


Diabetes and obesity in heart failure: a crossroads for prognosis and the efficacy of beta-blockers

Speaker: Professor D. Kotecha (Birmingham, GB)


Discussion - BB-meta-HF


Discussion - GENETIC-AF


Access the full session

Late breaking trial II - Chronic heart failure

Speakers: Professor W. Abraham, Professor T. Jaarsma, Professor D. Kotecha

About the event


Heart Failure 2018 & World Congress on Acute Heart Failure

26 May - 29 May 2018

Sessions Presentations

This platform is supported by

logo Novo Nordisk